Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
2.570
-0.060 (-2.28%)
Feb 21, 2025, 4:00 PM EST - Market closed
Geron Revenue
Geron had revenue of $28.27M in the quarter ending September 30, 2024, with 17,138.41% growth. This brings the company's revenue in the last twelve months to $29.48M, up 9,199.68% year-over-year. In the year 2023, Geron had annual revenue of $237.00K, down -60.23%.
Revenue (ttm)
$29.48M
Revenue Growth
+9,199.68%
P/S Ratio
54.81
Revenue / Employee
$209,078
Employees
141
Market Cap
1.55B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 237.00K | -359.00K | -60.23% |
Dec 31, 2022 | 596.00K | -797.00K | -57.21% |
Dec 31, 2021 | 1.39M | 1.14M | 450.59% |
Dec 31, 2020 | 253.00K | -207.00K | -45.00% |
Dec 31, 2019 | 460.00K | -606.00K | -56.85% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GERN News
- 16 hours ago - 3 Biotech/Healthcare Names Under $10 I Am Buying Now - Seeking Alpha
- 1 day ago - Geron to Participate at Upcoming Investor Conferences in March 2025 - Business Wire
- 2 days ago - Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch - Seeking Alpha
- 19 days ago - Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 - Business Wire
- 5 weeks ago - Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales - Seeking Alpha
- 2 months ago - Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS - Business Wire
- 2 months ago - Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies - Business Wire